Comparing Chemoradiotherapy Regimens for Pancreatic Cancer
Author Information
Author(s): Brunner Thomas B, Sauer Rolf, Fietkau Rainer
Primary Institution: Friedrich-Alexander University of Erlangen-Nuremberg
Hypothesis
Is gemcitabine/cisplatin more effective than 5-fluorouracil/mitomycin C in treating locally advanced pancreatic cancer?
Conclusion
Gemcitabine/cisplatin was found to be superior to 5-fluorouracil/mitomycin C for overall survival in patients with locally advanced pancreatic cancer.
Supporting Evidence
- The median overall survival was 12.7 months for the GC group and 9.7 months for the FM group.
- One-year overall survival rates were 53% for GC and 40% for FM.
- GC led to more grade 3 leukocytopenia and thrombocytopenia than FM.
Takeaway
This study looked at two treatments for pancreatic cancer and found that one treatment helped patients live longer than the other.
Methodology
A retrospective analysis of 93 patients treated with either 5-fluorouracil/mitomycin C or gemcitabine/cisplatin chemoradiotherapy.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective, which may introduce selection bias.
Participant Demographics
Patients had locally advanced pancreatic cancer, with a median age of 63 and a majority having cT4 tumors.
Statistical Information
P-Value
0.009
Statistical Significance
p = 0.009
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website